慢性粒细胞白血病患者的妊娠管理  

Pregnancy management of patients with chronic granulocyte leukemia

作　　者：裴娇娇 谢江燕[1] 黄超林 PEI Jiaojiao;XIE Jiangyan;HUANG Chaolin(Department of Obstetrics and Gynecology,the First Affiliated Hospital of Chengdu Medical School,Sichuan Chengdu 610500,China)

机构地区：[1]成都医学院第一附属医院妇产科,四川成都610500

出　　处：《现代肿瘤医学》2023年第16期3122-3126,共5页Journal of Modern Oncology

基　　金：四川省医学青年创新科研课题计划(编号:Q20075);四川省成都市卫生健康委员会科研项目(编号:2022657)。

摘　　要：随着慢性粒细胞白血病患者生存率的显著提高,越来越多的人要求解决与生活密切相关的生育问题,这也为慢性粒细胞白血病患者的妊娠管理提出挑战。尽管酪氨酸激酶抑制剂应用于慢性粒细胞白血病患者的临床治疗中,其安全性和有效性是毋庸置疑的,但该药对生育的影响和致畸作用限制了该药在妊娠中的应用,白细胞分离、干扰素和羟基脲等治疗方式成为妊娠期间慢性粒细胞白血病患者的另一个选择。在选择最佳的妊娠时机时,应该遵循个体化和多学科合作的原则,充分评估继续治疗对胎儿的危害和治疗中断对母亲的风险。通过本文综述,旨在为慢性粒细胞白血病患者的妊娠管理提供建议。As the significant improvement of the survival rate of patients with chronic myeloid leukemia,more and more people ask to solve fertility problems,which challenges the management of pregnant patients with chronic myeloid leukemia.Although there is no doubt about the safety and efficacy of tyrosine kinase inhibitor in the clinical treatment of patients with chronic myeloid leukemia,the effect of tyrosine kinase inhibitor on fertility and teratogenicity limits its application in pregnancy.Treatment methods such as leukocyte separation,interferon,and hydroxyurea have become other choices for patients with chronic myeloid leukemia during pregnancy.While choosing the best time for pregnancy,we should follow the principles of individualization and multidisciplinary cooperation,and fully assess the harm of continued treatment to the fetus and the risk of treatment interruption to the mother.The purpose of this review is to provide suggestions for pregnancy management in patients with chronic myeloid leukemia.

关 键 词：白血病 骨髓性 慢性 BCR-ABL阳性 妊娠 疾病管理 

分 类 号：R733.7[医药卫生—肿瘤]